Marengo Therapeutics

Share on: 

Marengo’s approach mimics natural mechanisms of non-clonal T cell receptor (TCR) activation, such as bacterial superantigen-induced TCR activation, and remodel the T cell compartment to unleash rapid, effective, and long-lasting anti-tumor responses. Marengo’s therapeutic antibodies prime the activation of clonally diverse T cell populations within both CD8+ and CD4+ effector pools, which drives potent anti-tumor activity by “turbocharged” T cells and promotes long-term tumor immunity via “memory” T cells.

Career Page(s): 
Cambridge MA
United States